Judge Approves Lehman Brothers $767M Settlement; Arrowhead Research Hits New 52-week High


Investment Opinion

Share Tweet

Judge Approves Lehman Brothers $767M Settlement; Arrowhead Research Hits New 52-week High

Twitter, Inc. (NYSE: TWTR) – For an in-depth report on Twitter, Inc. follow: www.BullTrends.com/stockquote/TWTR

Shares of Twitter closed down 4.61% on about 25 million shares despite the company releasing any news. It was revealed earlier in the week that roughly 10,000 racist slurs are posted daily on Twitter, according to a U.K. group that sees value in analyzing the multitudinous chatter on social media. Based on a nine-day survey of the Twitter TWTR +0.54% feed in November, the Centre for the Analysis of Social Media of the London-based Demos think tank recorded 10,000 racist or ethnic slurs, or one in every 15,000 tweets.

Federal National Mortgage Association (OTCBB: FNMA) – For an in-depth report on Federal National Mortgage Association follow: www.BullTrends.com/stockquote/FNMA

Shares of Federal National Mortgage Association closed up 8.97% on Wednesday with nearly 40 million shares. A U.S. Bankruptcy Court judge has approved Lehman Brothers Holdings Inc.'s $767 million settlement with Freddie Mac — an agreement that releases hundreds of millions of dollars to return to the failed investment bank's creditors. Freddie Mac was seeking a claim over $1.2 billion in loans that it made to Lehman before its collapse.

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) – For an in-depth report on Chelsea Therapeutics International Ltd. follow: www.BullTrends.com/stockquote/CHTP

Chelsea Therapeutics closed up 24.44% on Wednesday with nearly 45 million shares traded. The stock also hit a new 52-week high of $6.83 during intra-day trading. The big move came after it was revealed that the company has received accelerated approval from the U.S. Food and Drug Administration for Northera for the treatment of symptomatic neurogenic orthostatic hypotension. Chelsea Therapeutics expects to launch Northera in the second half of 2014. The approval was granted under the FDA’s accelerated approval program, which allows conditional approval of a drug for an unmet medical condition, provided additional studies are conducted.

Arrowhead Research Corp. (NASDAQ: ARWR) – For an in-depth report on Fresh Arrowhead Research Corp. follow: www.BullTrends.com/stockquote/ARWR

Shares of the closed up 11.29% on Wednesday and even hit a new 52-week high of $21.74 during intra-day trading. The company announced the pricing of an underwritten offering of 5,500,000 shares of its common stock, offered at a price of $18.95 per share. The offering is expected to close on or about February 24, 2014, subject to customary closing conditions. In addition, the company was featured in a SeekingAlpha article favorably with the title, “Arrowhead: A Functional Cure For The Hepatitis B Virus.”


Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/


Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.